Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seropersistence of TBE Virus Antibodies 3 Years After Booster with FSME-IMMUN 0.25 ml Junior in Children
2005-000768-19Phase 4Completed
- Sponsor
- Baxter International Inc.
- Start
- Jun 2005
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tick-borne encephalitis vaccine (inactivated) in tick-borne encephalitis (TBE), sponsored by Baxter International Inc. Primary endpoints: Seropositivity rate by ELISA and/or neutralization test and Seropositivity rate by ELISA. Started Jun 2005; status: completed.
02
Drugs
tick-borne encephalitis vaccine (inactivated)
03
Conditions
tick-borne encephalitis (TBE)
Beyond the preview
Go deeper on 2005-000768-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000768-19.